Immunic, Inc. IMUX
9.35
0.03
0.32%
as of 25 Sep
- Market cap
- $127.2M
- P/E
- 0.0×
Follow IMUX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
1.31 | 0.75 | 4.92 | 5.05 |
Net Debt/EBITDA |
1.35 | 0.66 | 5.62 | 4.39 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 1.00 | 0.53 | 0.91 | |
Capex/Depreciation |
(1.67) | (0.26) | (0.06) | (7.32) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.04) | (1.24) | (0.57) | (0.73) | |
Cash per Share |
1.81 | 0.99 | 6.19 | 3.65 | |
Shareholders Equity per Share |
0.54 | (0.43) | 5.02 | 3.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.54 | (0.43) | 5.02 | 3.00 | |
Free Cash Flow |
(20.21) | (19.29) | (17.30) | (31.25) | |
Working Capital |
9.19 | (7.75) | 150.40 | 126.57 | |
Capital Expenditures |
(0.07) | (0.01) | 0.00 | (0.25) | |
Net Current Asset Value |
9.07 | (7.86) | 150.25 | 126.25 | |
| Other line items | |||||
Quick Ratio |
1.17 | 0.51 | 4.86 | 4.96 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.04) | (1.24) | (0.57) | (0.73) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Average Payables |
6.98 | 8.99 | 8.51 | 10.28 | |
Average Assets |
52.73 | 32.46 | 105.13 | 110.30 | |
Average Common Equity |
25.86 | 5.88 | 72.97 | 80.75 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates